Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Explorer10: Concizumab Prophylaxis in Children With Haemophilia A or B
NCT05135559Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Mar 2022
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, open-label trial of concizumab in hemophilia A and Hemophilia B (HB) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treated spontaneous and traumatic bleeding episodes at 32 weeks. Started Mar 2022; status: active, not recruiting.
02
Drugs
concizumab
03
Conditions
hemophilia AHemophilia B (HB)
Beyond the preview
Go deeper on NCT05135559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135559.